Dennis Slamon ONCOLOGY Professor of Medicine; Chief, Division of Hematology/Oncology; Associate Director of ...

Cleveland Clinic researchers have found that nearly two-thirds of patients with HER2-positive metastatic breast cancer did not receive the guideline-recommended standard of care treatment between 2015 ...

This years 2026 ASCO Gastrointestinal Cancers Symposium was packed with practice-shaping data across colorectal and upper ...

Emerging immunotherapies and targeted therapies take aim at recently identified biomarkers ...

Biocon recently unveiled three new biosimilar oncology assets to its R&D pipeline —trastuzumab/hyaluronidase (Herceptin ...

Advanced gastroesophageal adenocarcinoma (GEA) with HER2 positivity has long presented significant treatment challenges, with ...

At the San Antonio Breast Cancer Symposium, researchers discussed how results from HER2CLIMB-05 may inform first-line ...

Swiss pharma giant Roche Holding AG's RHHBY 2025 results were affected by currency headwinds. Sales totaled $74.4 billion, ...

Eligible women with breast cancer in Thailand now have access to a new therapy, NERLYNX® (neratinib), for the first timeThe launch of NERLYNX provides an ...

The EMA validation of T-DXd with pertuzumab could change the standard of care for HER2-positive metastatic breast cancer in ...

Immunotherapy, targeted treatments, HIPEC, and new delivery options ...